secwatch / observer
8-K filed June 9, 2023, 7:59 PM ET ticker LGND CIK 0000886163
other material confidence high sentiment neutral materiality 0.15

Ligand annual meeting elects 7 directors, ratifies auditor, approves say-on-pay

LIGAND PHARMACEUTICALS INC

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

LIGAND PHARMACEUTICALS INC shareholders approved Approval of a non-binding advisory resolution regarding the compensation of the Company's named executive officers at the 2023-06-09 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2023-06-09
Exact text from the filing
Proposal 3 . The approval of a non-binding advisory resolution regarding the compensation of the Company’s named executive officers. In accordance with the results below, the resolution was approved. Votes For Votes Against Abstentions Broker Non-Votes 12,379,762 1,698,528 21,290 1,765,888
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

LIGAND PHARMACEUTICALS INC shareholders approved Election of seven members of the Board of Directors for terms expiring at the 2024 annual meeting at the 2023-06-09 meeting.

Proposal
director election
Outcome
passed
Meeting
2023-06-09
Exact text from the filing
Proposal 1. The election of seven members of the Board of Directors of the Company for terms expiring at the 2024 annual meeting of stockholders. In accordance with the results below, each nominee was elected to serve as a director. Votes For Votes Withheld Broker Non-Votes Jason M. Aryeh 7,967,581 6,131,999 1,765,888 Todd C. Davis 13,729,132 370,448 1,765,888 Nancy R. Gray, Ph.D. 13,426,347 673,233 1,765,888 Jason Haas 13,450,640 648,940 1,765,888 John W. Kozarich, Ph.D. 9,920,043 4,179,537 1,765,888 John L. LaMattina, Ph.D. 13,372,521 727,059 1,765,888 Stephen L. Sabba, M.D. 13,313,876 785,704 1,765,888
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

LIGAND PHARMACEUTICALS INC shareholders approved Approval of a non-binding advisory resolution regarding the frequency of the advisory vote on the compensation of the Company's named executive officers at the 2023-06-09 meeting.

Proposal
say on pay frequency
Outcome
passed
Meeting
2023-06-09
Exact text from the filing
Proposal 4 . The approval of a non-binding advisory resolution regarding the frequency of the advisory vote on the compensation of the Company’s named executive officers. Based on the results below, the Company has determined that it will hold a stockholder advisory vote on the compensation of the Company’s named executive officers every year. 1 Year 2 Years 3 Years Abstentions Broker Non-Votes 13,490,718 29,347 567,460 12,055 1,765,888
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

LIGAND PHARMACEUTICALS INC shareholders approved Ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-09 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2023-06-09
Exact text from the filing
Proposal 2. The ratification of the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. In accordance with the results below, the selection of Ernst & Young LLP was ratified. Votes For Votes Against Abstentions Broker Non-Votes 15,512,124 347,261 6,083 N/A
View on SEC.gov

Browse all shareholder votes →

LIGAND PHARMACEUTICALS INC filing history →

Source: SEC EDGAR
accession 0000886163-23-000030
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.